Dishman Carbogen Amcis announced that its wholly owned subsidiary, CARBOGEN AMCIS AG, has successfully completed a US Food and Drug Administration (FDA) inspection. The inspection, conducted at the Vionnaz, Switzerland manufacturing site, concluded without any observations (Form 483). This achievement underscores the company’s commitment to stringent quality standards across its global operations and reinforces the approval status of its sites by major regulatory bodies.
Subsidiary Achieves Milestone FDA Inspection
Dishman Carbogen Amcis Limited has received confirmation that its wholly owned subsidiary, CARBOGEN AMCIS AG, has successfully passed a critical inspection by the U.S. Food and Drug Administration (FDA). The inspection took place at the manufacturing facility located in Vionnaz, Switzerland. Importantly, the inspection concluded with zero observations (Form 483), indicating full compliance with FDA standards.
Commitment to Quality and Compliance
This successful FDA inspection highlights the strong emphasis Dishman Carbogen Amcis places on maintaining rigorous quality parameters across its entire group of companies and subsidiaries. The company stated that its manufacturing sites worldwide continue to be approved by leading regulatory agencies. This ongoing compliance ensures continued market access and strengthens the company’s reputation for reliability and quality in the pharmaceutical sector.
Source: BSE
